Increased Risk for Breast Cancer in Shift Workers Possibly Associated with Epigenetic Changes in Circadian Pathway

TON - March 2017, Vol 10, No 2 - Breast Cancer
Meg Barbor, MPH

Cape Town, South Africa—Occupational factors such as shift work disrupt circadian rhythm and can increase breast cancer risk, and the International Agency for Research on Cancer (the World Health Organization’s source for information about cancer) has classified shift work as a possible carcinogen. However, according to researchers at the National Institute of Occupational Health in Oslo, Norway, and the Nofer Institute of Occupational Medicine in Lodz, Poland, the mechanisms of increased cancer risk caused by shift work are not fully understood.

Circadian disruption may affect epigenetic factors such as 5-methyl cytosine methylation in DNA. DNA hypermethylation is associated with increased cancer risk if it occurs in tumor suppressor genes, and some circadian genes are known to function as tumor suppressor genes. The re­searchers, led by Shan Zienolddiny from the National Institute of Occupational Health, hypothesized that these aberrant epigenetic modifications caused by circadian disruption may be involved in the development of breast cancer.

The team conducted a nested breast cancer case-control study of female nurses working night shifts and presented their results in a poster at the American Association for Cancer Research International Conference on New Frontiers in Cancer Research. Changes in methylation levels in a number of core circadian and melatonin receptor genes were analyzed in 352 patients with breast cancer and 355 healthy controls.

Significantly higher methylation in the MTNR1A gene was observed in patients with cancer than in controls, and PR-A methylation was significantly increased in night workers compared with day workers. Based on these data, the investigators concluded that changes in methylation status of the genes that regulate circadian rhythm may be associated with increased breast cancer risk in workers with consecutive night shifts. However, further research is needed on the effects of work schedules on epigenetic changes.—MB

Related Items
Adding Immunotherapy to Chemotherapy Extends Survival in Metastatic Triple-Negative Breast Cancer
Phoebe Starr
TOP - February 2019, Vol 12, No 1 published on January 29, 2019 in Breast Cancer, Immunotherapy
Targeted Intervention Reduces Opioid Use by Nearly 50% After Urologic Oncology Surgery
Meg Barbor, MPH
TOP - February 2019, Vol 12, No 1 published on January 29, 2019 in Symptom Management Overview
Alpelisib First Drug to Improve Outcomes in Advanced Breast Cancer with PIK3CA Mutation
TOP - February 2019, Vol 12, No 1 published on January 29, 2019 in Breast Cancer
5-mg Tamoxifen as Effective as 20 mg Daily in Early Localized Breast Cancer
Phoebe Starr
JHOP Web Exclusives published on January 28, 2019 in Breast Cancer
Managing Bone Metastases Through a Multidisciplinary Approach
Meg Barbor, MPH
JHOP Web Exclusives published on December 11, 2018 in Supportive Care
Oral Toxicities Associated with Cancer Therapies: What's Old Is New Again
Meg Barbor, MPH
JHOP Web Exclusives published on November 26, 2018 in Drug Therapies
The Pharmacist’s Role in Improving Quality in Oncology
Meg Barbor, MPH
TOP - November 2018, Vol 11, No 3 published on November 21, 2018 in HOPA 2018 Highlights
CAR T-Cell Therapy: Can We Afford the Cure?
Meg Barbor, MPH
TOP - November 2018, Vol 11, No 3 published on November 21, 2018 in HOPA 2018 Highlights
Harnessing the Power of Business Intelligence to Influence Oncology Practice
Meg Barbor, MPH
TOP - November 2018, Vol 11, No 3 published on November 21, 2018 in HOPA 2018 Highlights
Less Is More: 6 Months of Trastuzumab Treatment Equivalent to 12 Months in HER2-Positive Breast Cancer
Phoebe Starr
TOP - November 2018, Vol 11, No 3 published on November 21, 2018 in Breast Cancer
Last modified: March 14, 2017